BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30652208)

  • 21. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.
    Teng MW; Swann JB; von Scheidt B; Sharkey J; Zerafa N; McLaughlin N; Yamaguchi T; Sakaguchi S; Darcy PK; Smyth MJ
    Cancer Res; 2010 Apr; 70(7):2665-74. PubMed ID: 20332236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
    Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
    Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells.
    Shan J; Feng L; Sun G; Chen P; Zhou Y; Xia M; Li H; Li Y
    Immunobiology; 2015 Apr; 220(4):510-7. PubMed ID: 25468562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.
    Desar IM; Jacobs JH; Hulsbergen-vandeKaa CA; Oyen WJ; Mulders PF; van der Graaf WT; Adema GJ; van Herpen CM; de Vries IJ
    Int J Cancer; 2011 Jul; 129(2):507-12. PubMed ID: 20839259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
    van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
    Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
    Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.
    Pohla H; Buchner A; Stadlbauer B; Frankenberger B; Stevanovic S; Walter S; Frank R; Schwachula T; Olek S; Kopp J; Willimsky G; Stief CG; Hofstetter A; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
    Mol Med; 2013 Feb; 18(1):1499-508. PubMed ID: 23269976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
    Guislain A; Gadiot J; Kaiser A; Jordanova ES; Broeks A; Sanders J; van Boven H; de Gruijl TD; Haanen JB; Bex A; Blank CU
    Cancer Immunol Immunother; 2015 Oct; 64(10):1241-50. PubMed ID: 26105626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of interleukin-2 treatment on CD1d-restricted natural killer T cells.
    Sandberg JK; Moll M
    Clin Cancer Res; 2007 Jul; 13(14):4311; author reply 4311-2. PubMed ID: 17634562
    [No Abstract]   [Full Text] [Related]  

  • 30. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
    Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced dendritic cell-based immunotherapy using low-dose cyclophosphamide and CD25-targeted antibody for transplanted Lewis lung carcinoma cells.
    Son CH; Bae JH; Lee HR; Shin DY; Yang K; Park YS
    J Immunother; 2015 Apr; 38(3):107-15. PubMed ID: 25751500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.
    Garcia JA; Mekhail T; Elson P; Triozzi P; Nemec C; Dreicer R; Bukowski RM; Rini BI
    BJU Int; 2011 Feb; 107(4):562-70. PubMed ID: 20840548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.
    Attig S; Hennenlotter J; Pawelec G; Klein G; Koch SD; Pircher H; Feyerabend S; Wernet D; Stenzl A; Rammensee HG; Gouttefangeas C
    Cancer Res; 2009 Nov; 69(21):8412-9. PubMed ID: 19843860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model.
    Son CH; Shin DY; Kim SD; Park HS; Jung MH; Bae JH; Kang CD; Yang K; Park YS
    J Immunother; 2012 Oct; 35(8):607-14. PubMed ID: 22996366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs.
    Elkord E; Sharma S; Burt DJ; Hawkins RE
    Clin Immunol; 2011 Sep; 140(3):218-22. PubMed ID: 21570917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.
    Stein A; Bellmunt J; Escudier B; Kim D; Stergiopoulos SG; Mietlowski W; Motzer RJ;
    Eur Urol; 2013 Dec; 64(6):994-1002. PubMed ID: 23219086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunosuppressive Effects and Potent Anti-tumor Efficacy of mTOR Inhibitor Everolimus in Breast Tumor-bearing Mice.
    Rostamzadeh D; Haghshenas MR; Samadi M; Mojtahedi Z; Babaloo Z; Ghaderi A
    Iran J Allergy Asthma Immunol; 2022 Jun; 21(3):287-299. PubMed ID: 35822679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):512-3. PubMed ID: 26351813
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.